<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Drugs that elevate the serum creatinine concentration
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Drugs that elevate the serum creatinine concentration
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Drugs that elevate the serum creatinine concentration
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lesley A Inker, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronald D Perrone, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         An elevation in the serum creatinine concentration (SCr) usually reflects a reduction in the glomerular filtration rate and is associated with a concomitant rise in the blood urea nitrogen (BUN). (See
         <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">
          "Assessment of kidney function"
         </a>
         .)
        </p>
        <p>
         There are, however, a variety of settings in which the SCr can increase acutely independent of a decrease in the glomerular filtration rate (GFR), and, therefore, in which there is no true change in overall kidney function. This may be due to one of three factors: decreased creatinine secretion, interference with the serum assay, or enhanced creatinine production.
        </p>
        <p>
         Thus, in patients taking one of the drugs described below, an elevation of creatinine without a concomitant elevation of BUN does
         <strong>
          not
         </strong>
         likely reflect a true decrease in GFR.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DECREASED SECRETION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In normal subjects, approximately 15 percent of the urinary creatinine is derived from secretion in the proximal tubule. This value can rise to as high as 50 percent in patients with advanced kidney disease and accounts for the overestimation of the true glomerular filtration rate (GFR) by the creatinine clearance [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2378.html" rel="external">
          "Calculation of the creatinine clearance"
         </a>
         .)
        </p>
        <p>
         Creatinine is an organic cation in the physiologic pH range and is secreted by the organic cation secretory pump and the solute carrier family 47 member 1 (SLC47A1) transporter (also known as multidrug and toxin extrusion 1, or MATE1), and secretion can be inhibited by other organic cations. Certain drugs can interfere with creatinine secretion via these proteins and therefore result in a reversible rise in the SCr. The magnitude of the rise depends upon the proportion of creatinine that is secreted (versus filtered) as well as the specific drug that is inhibiting transport. Commonly used drugs that elevate the serum creatinine include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antimicrobial
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         (which is most often given in combination with sulfamethoxazole) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antiarrhythmic drug
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         (which is used in some patients with atrial fibrillation) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The H
         <sub>
          2
         </sub>
         blocker,
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         [
         <a href="#rid4">
          4,5
         </a>
         ].
         <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">
          Famotidine
         </a>
         , which is another commonly used H
         <sub>
          2
         </sub>
         blocker, has a much less prominent effect on creatinine handling [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effect of
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         has been used clinically to improve the accuracy of the creatinine clearance [
         <a href="#rid4">
          4,6,7
         </a>
         ]. By competitively inhibiting creatinine secretion, the creatinine clearance becomes a more accurate measure of the true glomerular filtration rate. (See
         <a class="medical medical_review" href="/z/d/html/2378.html" rel="external">
          "Calculation of the creatinine clearance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          Dolutegravir
         </a>
         and
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         , which are two drugs used in the treatment of HIV, can increase serum creatinine and decrease estimated GFR due to decreases in creatinine secretion [
         <a href="#rid8">
          8-11
         </a>
         ]. Dolutegravir blocks the uptake of creatinine from the blood by inhibiting an organic cation transporter, whereas cobicistat affects the efflux of creatinine by inhibiting SLC47A1 [
         <a href="#rid7">
          7
         </a>
         ]. Increases in SCr occur within the first four weeks of therapy and plateaued thereafter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The poly-ADP ribose polymerase (PARP) inhibitors such as
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         and
         <a class="drug drug_general" data-topicid="111396" href="/z/d/drug information/111396.html" rel="external">
          rucaparib
         </a>
         , which are used to treat certain types of cancer, may inhibit proximal tubule transporters, including organic cation transporters and SLC47A1, thereby reducing creatinine secretion [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tyrosine kinase inhibitors, such as
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         , and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="16810" href="/z/d/drug information/16810.html" rel="external">
          crizotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         may inhibit SLC47A1-mediated secretion of creatinine and thereby elevated the SCr [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antiparasitic drug
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         , which is used as a second-line drug for prophylaxis or treatment of toxoplasmosis and
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia, interferes with tubular creatinine secretion [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          INTERFERENCE WITH THE SERUM ASSAY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum creatinine is most often measured by the alkaline picrate method. This colorimetric assay can recognize other compounds as creatinine chromogens, particularly acetoacetate in diabetic ketoacidosis [
         <a href="#rid18">
          18
         </a>
         ]. In this setting, the SCr can rise by 0.5 to 2 mg/dL or more (44 to 176 micromol/L), a change that is rapidly reversed with insulin therapy.
         <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">
          Cefoxitin
         </a>
         and
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         are other drugs that can produce a similar effect [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
         The Ektachem (Eastman Kodak Co., Rochester, New York) method, using the enzyme creatinine iminohydrolase, and the creatinine PAP method (Boehringer Mannheim, Mannheim, Germany), using the enzymes creatininase, creatinase, and sarcosine oxidase, yield creatinine values comparable to those obtained using the kinetic alkaline picrate method. In general, these methods appear to have less interferences than the alkaline picrate methods, but there are reports of interfering substances [
         <a href="#rid21">
          21
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antifungal agent
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         interferes with the Ektachem measurement; it may increase the value by as much as 60 percent [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A proline stabilizer infused with intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) therapy produced increased serum creatinine in one report [
         <a href="#rid25">
          25
         </a>
         ]. The elevated creatinine measurement was due to positive interference in the enzymatic creatinine assay, likely due to the activity of sarcosine oxidase on proline.
        </p>
        <p>
        </p>
        <p>
         It seems likely in the future that more specific assays for creatinine will eliminate the problem of drug interference. One possible method is the use of an artificial receptor that is specific for creatinine and that undergoes a color change when creatinine is bound [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ENHANCED CREATININE PRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The SCr varies during the day, rising by as much as 0.5 to 1 mg/dL (44 to 88 micromol/L) after a large cooked meat meal (since muscle contains creatine, which is converted to creatinine by the heat from cooking) and then returning slowly to the baseline level [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         It has also been suggested that the SCr rises more rapidly with rhabdomyolysis (up to 2.5 mg/dL or 220 micromol/L per day) than with other causes of acute kidney injury [
         <a href="#rid28">
          28
         </a>
         ]. Release of preformed creatinine from injured muscle and/or release of creatine that is then converted into creatinine in the extracellular fluid have been proposed to explain this finding. However, neither of these mechanisms appear to account for the increase in the SCr [
         <a href="#rid29">
          29
         </a>
         ]. An alternative explanation is that rhabdomyolysis often affects men with a high muscle mass and a higher rate of creatinine production than seen in frequently ill patients with other forms of acute kidney injury [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         <strong>
          Creatine supplements
         </strong>
         are increasingly used in health and disease. For most people, this will not lead to increases in serum creatinine levels (or declines in estimated glomerular filtration rate [GFR]). One randomized control trial of patients with diabetes showed no effect on GFR measured using (51)Cr-EDTA clearance [
         <a href="#rid30">
          30
         </a>
         ], despite higher muscle phosphoryl creatine.
        </p>
        <p class="headingAnchor" id="H22322751">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A variety of drugs can affect the serum creatinine level. There are two primary mechanisms for this. The drug may compete with the secretion of creatinine at the level of the kidney tubule or may interfere with the assay. Increased intake of creatine and creatinine may also elevate the level of creatinine in the blood, independent of glomerular filtration rate. (See
         <a class="local">
          'Decreased secretion'
         </a>
         above and
         <a class="local">
          'Interference with the serum assay'
         </a>
         above and
         <a class="local">
          'Enhanced creatinine production'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg KJ, Gjellestad A, Nordby G, et al. Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients. Nephron 1989; 53:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duncker D, Oswald H, Gardiwal A, et al. Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine. J Cardiovasc Pharmacol Ther 2013; 18:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991; 40:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocci ML Jr, Vlasses PH, Ferguson RK. Creatinine serum concentrations and H2-receptor antagonists. Clin Nephrol 1984; 22:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemperman FA, Silberbusch J, Slaats EH, et al. Follow-up of GFR estimated from plasma creatinine after cimetidine administration in patients with diabetes mellitus type 2. Clin Nephrol 2000; 54:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tangri N, Alam A, Edwardes MD, et al. Evaluating cimetidine for GFR estimation in liver transplant recipients. Nephrol Dial Transplant 2010; 25:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindeman TA, Duggan JM, Sahloff EG. Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults. Open Forum Infect Dis 2016; 3:ofw053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 2014; 86:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormick A, Swaisland H. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib. Xenobiotica 2017; 47:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer: focus on rucaparib. Int J Womens Health 2017; 9:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omote S, Matsuoka N, Arakawa H, et al. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep 2018; 8:9237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vidal-Petiot E, Rea D, Serrano F, et al. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2016; 16:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Gambacorti-Passerini C, Kim DW, et al. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk 2017; 17:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opravil M, Keusch G, Lüthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother 1993; 37:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980; 93:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saah AJ, Koch TR, Drusano GL. Cefoxitin falsely elevates creatinine levels. JAMA 1982; 247:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell EK. Flucytosine and false elevation of serum creatinine level. Ann Intern Med 1984; 101:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CH, Landt M, Steelman M, Ladenson JH. The Kodak Ektachem 400 Analyzer evaluated for automated enzymic determination of plasma creatinine. Clin Chem 1983; 29:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble MA, Harper B, Grant AG, Bernstein M. Rapid determination of 5-fluorocytosine levels in blood. J Clin Microbiol 1984; 20:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrington D, Drusano GL, Smalls U, Standiford HC. False elevation in serum creatinine levels. JAMA 1984; 252:2962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knezevic CE, Ness MA, Kratz LE, Marzinke MA. Elevated creatinine in a patient on IVIG-therapy. Clin Chim Acta 2018; 486:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell TW, Hou Z, Luo Y, et al. Detection of creatinine by a designed receptor. Science 1995; 269:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne RB. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 1986; 23 ( Pt 3):243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton RW, Gardner LB, Penn AS, Goldberg M. Acute tubular necrosis caused by exercise-induced myoglobinuria. Ann Intern Med 1972; 77:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh MS. Does serum creatinine rise faster in rhabdomyolysis? Nephron 1993; 63:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gualano B, de Salles Painelli V, Roschel H, et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol 2011; 111:749.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2361 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2418254" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Limitations of creatinine as a filtration marker in glomerulopathic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2677807" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22837540" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1762320" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cimetidine improves the reliability of creatinine as a marker of glomerular filtration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6150778" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Creatinine serum concentrations and H2-receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11076100" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Follow-up of GFR estimated from plasma creatinine after cimetidine administration in patients with diabetes mellitus type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20037175" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evaluating cimetidine for GFR estimation in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27092314" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22905856" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24646860" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22732469" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27684210" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29290694" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Emerging treatment options for ovarian cancer: focus on rucaparib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29915248" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26795084" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28807791" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8517692" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pyrimethamine inhibits renal secretion of creatinine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6773457" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Spurious serum creatinine elevations in ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7053461" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cefoxitin falsely elevates creatinine levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6742655" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Flucytosine and false elevation of serum creatinine level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16332993" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6861349" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Kodak Ektachem 400 Analyzer evaluated for automated enzymic determination of plasma creatinine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6511883" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Rapid determination of 5-fluorocytosine levels in blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6502857" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : False elevation in serum creatinine levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30040921" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Elevated creatinine in a patient on IVIG-therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7624796" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Detection of creatinine by a designed receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3789633" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Creatinine clearance: a redundant clinical investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4626386" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acute tubular necrosis caused by exercise-induced myoglobinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8446260" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Does serum creatinine rise faster in rhabdomyolysis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20976468" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
